PERSEUS1: A Phase II trial of Pembrolizumab in patients with mCRPC
Research type
Research Study
Full title
PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab For Patients Suffering from Metastatic Prostate Cancer.
IRAS ID
208952
Contact name
Johann de Bono
Contact email
Eudract number
2017-000931-15
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
With an increased understanding of the genes involved in metastatic castrate resistant prostate cancer (mCRPC), and with the majority of patients potentially having some faulty genes, also known as mustations, there is a need to run a study to identify patients with specific faulty genes and test new agents that are targeted towards treating cancers with these faulty genes.
Pembrolizumab is a useful anticancer treatment in advanced melanoma, metastatic non-small cell lung cancer and metastatic urothelial cancer. Scientists believe that there is a group of prostate cancer patients who may also benefit from this targeted treatment.
The study will recruit up to 100 patients with mCRPC that is no longer responding to standard treatment and who have been identified as having specific faulty genes that are anticipated to respond to pembrolizumab treatment. These faulty genes will have been identified through a screening study for patients with prostate cancer that identifies faulty genes from a blood, tumour tissue and saliva samples.
The main aim of the study is to assess whether pembrolizumab is effective in treating mCRPC patients with these faulty genes.
REC name
London - Chelsea Research Ethics Committee
REC reference
18/LO/0825
Date of REC Opinion
25 Jun 2018
REC opinion
Favourable Opinion